2026· The Innovation Drug Discovery· 0 citations· 124 references
TL;DR
By delineating how physics-based priors synergize with data-driven representation learning, this review provides a comprehensive roadmap for generating physically plausible and thermodynamically stable therapeutics, ultimately accelerating the transition of computationally designed molecules from in silico blueprints to viable clinical candidates.
Abstract
Targeted drug discovery is fundamentally bottlenecked by the challenge of accurately modeling complex biomolecular interactions, ranging from small-molecule ligand binding to high-order macromolecular assemblies. While traditional physics-based computational methods provide profound mechanistic insights, their clinical utility is frequently hampered by prohibitive computational costs and scalability limitations when addressing highly flexible, cross-scale systems. Conversely, the rapid emergence of pure deep learning offers unprecedented computational speed but suffers from a fundamental “black-box” nature, sometimes yielding physically improbable conformations—often referred to as “hallucinations”—that can pose challenges in real-world experimental validation. To bridge this critical translational gap, the integration of physical principles with artificial intelligence—Physics-Informed Deep Learning (PIDL)—is currently driving a fundamental transition from purely empirical approximations to rational, physically grounded design. This review constructs a strategic framework to critically evaluate these transformative advances, structured around three methodological pillars: (1) Physics-constrained optimization, which integrates thermodynamic principles and integrative experimental restraints at the output level to decode macromolecular dynamics; (2) Physics-encoded architectures, which embed appropriate SE(3) or E(3) geometric symmetries directly into neural network topologies for precise structural recognition; and (3) Physics-guided representations, which project discrete sequences into continuous physicochemical manifolds to enhance interaction prediction. By delineating how physics-based priors synergize with data-driven representation learning, this review not only synthesizes current algorithmic breakthroughs but also provides a comprehensive roadmap for generating physically plausible and thermodynamically stable therapeutics, ultimately accelerating the transition of computationally designed molecules from in silico blueprints to viable clinical candidates.
It is argued that, since physics-based simulations and machine learning provide complementary approximations to the underlying probability distribution associated with biomolecular recognition events, and they excel respectively in consistency with free-energy landscapes and state populations and in predictive accuracy...
R. Khalil, Elena Frasnetti, Han Kurt et al.· Journal of Physical Chemistr...· 0 citations
Modelling sequences both “dry” and in the presence of explicit potassium cations are suggested as a simple, practical way to sample alternative conformations and to expose disordered regions that current predictors tend to over-fold.
Deep neural network (DNN)‐based in silico models show great promise in predicting the properties and bioactivities of novel compounds, including small molecules. Among traditional approaches, structure‐based drug design (SBDD) remains a fundamental approach for drug discovery using molecular docking, scoring functions,...
A. Srivastav, Unnati Modi, Rahul Kumar et al.· Molecular Informatics· 1 citation
PML is introduced, a novel computational framework that describes a binding interface as a family of multiscale manifolds, and results indicate that much of what determines binding strength is encoded in the shape of the interface itself, and that a single geometric description serves both classes without hand-tailored...
Xingjian Xu, Zhe Su, Guo-Wei Wei et al.· arXiv.org· 0 citations
A comprehensive review of how Artificial Intelligence and Machine Learning are redefining this landscape across three critical dimensions outlines the transition toward end‐to‐end, adaptive discovery systems that ensure computational hits are biologically potent, structurally optimized, and synthetically accessible.
Yi-Fei Wang, Nupur Bansal, Shiyun Wa et al.· WIREs Computational Molecula...· 0 citations
Current structure-based drug design generative models often struggle to faithfully recapitulate genuine ligand-protein binding interactions. Instead, under the coupling of implicit learning architectures and biased training data, they tend to learn spurious statistical correlations. To address this, we propose EIP-Diff...
Huabin Du, Mingyang Wang, M. Luo et al.· Journal of the American Chem...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.